A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)

NCT04237116 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Low enrollment

Conditions

Plaque Psoriasis
Non-alcoholic Fatty Liver Disease

Interventions

BIOLOGICAL: Investigational Arm - secukinumab
BIOLOGICAL: Control Arm - placebo

Sponsor

Novartis Pharmaceuticals